Evidence map›Paper›PMID 39097123›Full record

ArticleActa biomaterialia2024

Extracellular matrix regulation of cell spheroid invasion in a 3D bioprinted solid tumor-on-a-chip.

Elvan Dogan, Christopher A Galifi, Berivan Cecen, Roshni Shukla, Teresa L Wood, Amir K Miri

Abstract read
In one paragraph

Article in Acta biomaterialia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Microphysiological systems for metastasis research: a stepwise approach.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Organoids technology in cancer research: from basic applications to advancedFrontiers in cell and developmental biology · 2025
    Review
  16. Article
  17. Gene Expression ofIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elvan DoganDepartment of Biomedical Engineering, Newark College of Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
Christopher A GalifiDepartment of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Berivan CecenDepartment of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, USA.
Roshni ShuklaDepartment of Biomedical Engineering, Newark College of Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
Teresa L WoodDepartment of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Amir K MiriDepartment of Biomedical Engineering, Newark College of Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA; Department of Mechanical and Industrial Engineering, Newark College of Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA. Electronic address: am3296@njit.edu.

Funding

Pathways that regulate basal and metastatic phenotypes in triple negative breast cancersR01CA204312 · NCI · RBHS-NEW JERSEY MEDICAL SCHOOL · PI WOOD, TERESA L · 2017 to 2021
$2.7M
Bioprintable composite materials and microfluidic tools for vocal fold restoration and repairR01DC018577 · NIDCD · MCGILL UNIVERSITY · PI MONGEAU, LUC · 2021 to 2025
$2.5M
NCI NIH HHS R01 CA204312NIDCD NIH HHS R01 DC018577
6 · The paper itself

Abstract

Tumor organoids and tumors-on-chips can be built by placing patient-derived cells within an engineered extracellular matrix (ECM) for personalized medicine. The engineered ECM influences the tumor response, and understanding the ECM-tumor relationship accelerates translating tumors-on-chips into drug discovery and development. In this work, we tuned the physical and structural characteristics of ECM in a 3D bioprinted soft-tissue sarcoma microtissue. We formed cell spheroids at a controlled size and encapsulated them into our gelatin methacryloyl (GelMA)-based bioink to make perfusable hydrogel-based microfluidic chips. We then demonstrated the scalability and customization flexibility of our hydrogel-based chip via engineering tools. A multiscale physical and structural data analysis suggested a relationship between cell invasion response and bioink characteristics. Tumor cell invasive behavior and focal adhesion properties were observed in response to varying polymer network densities of the GelMA-based bioink. Immunostaining assays and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) helped assess the bioactivity of the microtissue and measure the cell invasion. The RT-qPCR data showed higher expressions of HIF-1α, CD44, and MMP2 genes in a lower polymer density, highlighting the correlation between bioink structural porosity, ECM stiffness, and tumor spheroid response. This work is the first step in modeling STS tumor invasiveness in hydrogel-based microfluidic chips. STATEMENT OF SIGNIFICANCE: We optimized an engineering protocol for making tumor spheroids at a controlled size, embedding spheroids into a gelatin-based matrix, and constructing a perfusable microfluidic device. A higher tumor invasion was observed in a low-stiffness matrix than a high-stiffness matrix. The physical characterizations revealed how the stiffness is controlled by the density of polymer chain networks and porosity. The biological assays revealed how the structural properties of the gelatin matrix and hypoxia in tumor progression impact cell invasion. This work can contribute to personalized medicine by making more effective, tailored cancer models.

Indexed as

BioprintingExtracellular MatrixGelatinHydrogelsPrinting, Three-DimensionalSpheroids, CellularCell Line, TumorHumansHypoxia-Inducible Factor 1, alpha SubunitLab-On-A-Chip DevicesMatrix Metalloproteinase 2MethacrylatesNeoplasm InvasivenessGelatingelatin methacryloylHydrogelsHypoxia-Inducible Factor 1, alpha SubunitMatrix Metalloproteinase 2MethacrylatesBioprintingGelatinMechanobiologyMicrostructureSolid tumor spheroid

Identifiers

PMID39097123
PMCPMC11390304

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.